Spyre Therapeutics, Inc. (SYRE) Misses Q3 EPS by 54c

Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q3 EPS of ($1.36), $0.54 worse than the analyst estimate of ($0.82).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.

You May Also Be Interested In

• Barrick Is Said to Weigh Delaying North America Gold IPO to 2027 - Bloomberg
• Fed watchdog calls for stronger controls on information sharing
• Yatsen Holding (YSG) Reports Q2 Loss of $0.16